Our Work in Neurology

The multiple sclerosis (MS) market is more dynamic than ever with more than 14 disease-modifying therapies (DMTs) currently available. In addition, evolving attitudes around safety issues balanced with earlier treatment with aggressive therapy has made the competitive environment increasingly complex. With the launch of the first anti-CGRP agent, the migraine market gains a new class which will shift current competitive patterns.

VIEW SERVICES OFFERED IN THIS AREA

Diseases Covered

Multiple Sclerosis, Migraine, Rare Neurological Diseases

Board of Advisors

Coming soon.

Advocacy Groups

The primary objectives of advocacy groups are to educate, advocate, collaborate, and improve the efficiency of services for individuals with MS and those who are close to them.

RECENT PUBLICATIONS

Overall Share of Ocrevus Remains Stable Among Recent New Start Patients, Yet Genentech’s Efforts to Increase First-Line Use Appears to be Paying Off in the Dominant Relapsing-Remitting Multiple Sclerosis Subgroup – February 11, 2020
>VIEW ARTICLE

Amgen/Novartis’ Aimovig Label Revision and Teva’s Ajovy Autoinjector Delay Clear the Way for Continued Growth of Eli Lilly’s Emgality in the US Migraine Prevention Market, According to Spherix Global Insights – December 18, 2019
>VIEW ARTICLE

UPCOMING CONFERENCES

AAN 2020
>LEARN MORE

AHS 2020
>LEARN MORE

HELPFUL LINKS

MSAA Logo
National MS Society Logo